Heron Therapeutics, Inc. (NASDAQ:HRTX - Get Free Report) saw some unusual options trading on Wednesday. Stock investors acquired 41,901 put options on the company. This represents an increase of approximately 3,838% compared to the typical volume of 1,064 put options.
Institutional Trading of Heron Therapeutics
Institutional investors and hedge funds have recently made changes to their positions in the stock. Orbimed Advisors LLC acquired a new stake in shares of Heron Therapeutics during the first quarter worth $7,855,000. BlackRock Inc. purchased a new stake in shares of Heron Therapeutics in the second quarter valued at $4,503,000. Tejara Capital Ltd acquired a new position in Heron Therapeutics in the second quarter valued at $2,779,000. Pale Fire Capital SE increased its stake in Heron Therapeutics by 84.8% in the first quarter. Pale Fire Capital SE now owns 2,716,328 shares of the biotechnology company's stock valued at $2,173,000 after purchasing an additional 1,246,673 shares during the last quarter. Finally, GSA Capital Partners LLP acquired a new position in Heron Therapeutics in the second quarter valued at $445,000. 80.01% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
A number of equities analysts have recently commented on the stock. HC Wainwright cut shares of Heron Therapeutics from a "buy" rating to a "neutral" rating in a report on Tuesday, August 11th. Wall Street Zen upgraded shares of Heron Therapeutics to a "sell" rating in a research report on Saturday, August 8th. Zacks Research upgraded shares of Heron Therapeutics from a "strong sell" rating to a "hold" rating in a research note on Monday, August 3rd. Finally, Weiss Ratings restated a "sell (e+)" rating on shares of Heron Therapeutics in a research note on Thursday, October 15th. Three analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Heron Therapeutics has an average rating of "Reduce" and a consensus price target of $2.00.
View Our Latest Analysis on Heron Therapeutics
Heron Therapeutics Price Performance
NASDAQ HRTX traded down $0.01 during trading hours on Wednesday, reaching $0.28. The company's stock had a trading volume of 1,255,950 shares, compared to its average volume of 3,150,451. The company has a debt-to-equity ratio of 32.59, a quick ratio of 1.31 and a current ratio of 2.33. The company's 50-day moving average is $0.32 and its two-hundred day moving average is $0.64. Heron Therapeutics has a fifty-two week low of $0.26 and a fifty-two week high of $1.57. The stock has a market cap of $52.51 million, a PE ratio of -2.30 and a beta of 1.65.
Heron Therapeutics (NASDAQ:HRTX - Get Free Report) last issued its quarterly earnings data on Monday, November 9th. The biotechnology company reported ($0.03) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.03). The firm had revenue of $35.25 million during the quarter, compared to the consensus estimate of $37.50 million. Heron Therapeutics had a negative return on equity of 277.36% and a negative net margin of 14.55%. Analysts forecast that Heron Therapeutics will post -0.15 EPS for the current year.
About Heron Therapeutics
(
Get Free Report)
Heron Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing treatments for patients in acute care settings, including cancer treatment and surgery. Its work includes medicines intended to prevent nausea and vomiting associated with chemotherapy and surgery, as well as treatments for postsurgical pain. Heron's products include CINVANTI and APONVIE, injectable formulations of aprepitant used to help prevent nausea and vomiting in specified clinical settings. The company also developed ZYNRELEF, a combination of bupivacaine and meloxicam for postsurgical pain, and SUSTOL, an extended-release formulation of granisetron for chemotherapy-related nausea and vomiting.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Heron Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Heron Therapeutics wasn't on the list.
While Heron Therapeutics currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.